Screener
GeneDx Holdings WGS Q2 2026 earnings
Reported August 3, 2026 · After market close
Revenue$114.4MBeat by $3.4M
EPS$0.01Beat by $0.20
Revenue estimate$111.0M
EPS estimate-$0.19
“Our team's unwavering focus and agility drove a strong second quarter. By delivering healthy revenue, volume, and gross margin growth, we successfully navigated our return to profitability. We are managing the transition to genome testing, making progress on each of our key imperatives — optimizing unit economics, growing utilization, and delivering the best products at unmatched scale — while continuing to extend our industry-leading position in both exome and genome testing to reach as many patients and families as soon as possible.”
Next report
Oct 27, 2026 (in a month)Revenue estimate$123.0M
EPS estimate$0.07
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did GeneDx Holdings report Q2 2026 earnings?
- GeneDx Holdings (WGS) reported Q2 2026 earnings on August 3, 2026 after market close.
- What were GeneDx Holdings's Q2 2026 revenue and EPS?
- GeneDx Holdings reported revenue of $114.4M and eps of $0.01 for Q2 2026.
- Did GeneDx Holdings beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $111.0M by $3.4M. EPS beat the consensus estimate of $-0.19 by $0.20.
- How did GeneDx Holdings's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 11.4% from $102.7M a year earlier and eps declined 98.0% from $0.50.
- Where can I find GeneDx Holdings's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-051852) and the 10-Q periodic report (0001628280-26-051878) directly on SEC EDGAR. The filing index links above go to sec.gov.
